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Abstract
Background: Temozolomide (TMZ) induces a G2/M cell cycle arrest and is used for treatment of paediatric tumours,
especially neuroblastomas. Patients treated with TMZ frequently receive midazolam for sedation prior to surgery and
other interventions. Previous studies suggested both cytoprotective and apoptosis-inducing properties of midazolam.
Therefore, the impact of midazolam on TMZ-induced cytotoxicity was investigated in vitro.
Methods: Human neuroblastoma cells were incubated with midazolam alone, as a pretreatment prior to incubation
with TMZ or a coincubation of both. Cell viability and proliferation was analysed (XTT and BrdU assay) after 24 h and
flowcytometric cell cycle analysis was performed after 24 and 48 h.
Results: Midazolam alone increased cell viability at lower concentrations (2, 4, 8, 16 μM), whereas higher concentrations
(128, 256, 512 μM) reduced cell viability. Pretreatment with midazolam 6 h prior to TMZ incubation reduced cytotoxic
effects (IC25 1005 ± 197 μM; IC50 1676 ± 557 μM; P < 0.05) compared to incubation with TMZ alone (IC25 449 ± 304 μM;
IC50 925 ± 196 μM) and reduced the antiproliferative effect of TMZ (1000 μM) by 43.9 % (P < 0.05). In contrast, cytotoxic
effects of TMZ were increased (IC75 1175 ± 221 μM vs. 2764 ± 307 μM; P < 0.05) when midazolam pretreatment was
followed by coincubation of midazolam and TMZ. Cell cycle analysis revealed increased fractions of cells in G2/M phase
after TMZ treatment (100 μM; 48 h), irrespective of midazolam pretreatment.
Conclusion: Midazolam causes a hormetic dose–response relationship in human neuroblastoma cells. Pretreatment with
midazolam reduces the cytotoxic and antiproliferative effects of TMZ without interfering with G2/M cell cycle arrest. In
contrast, subsequent midazolam coincubation increases overall cytotoxicity.
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Background
In the past decade, the relevance of temozolomide (TMZ),
a DNA-methylating agent, for the treatment of paediatric
solid tumours, especially neuroblastomas, has been eluci-
dated [1–6]. There is evidence, that even relapsed or re-
fractory tumours respond to TMZ alone or in
combination with other cytostatic agents [1–3, 7]. TMZ
acts as a prodrug, which is spontaneously converted to the
cytotoxic compound 5-(3-methyltriazen-1-yl) imidazole-
4-carbozamide (MTIC) and alkylates guanine in genomic
DNA at position O6 with subsequent impaired DNA-
repair and G2/M arrest [8]. Reduction of the cytotoxic
effect of TMZ by concomitant medication might reduce
the effectiveness of anticancer regimen.
Midazolam is one of the most common sedatives for
paediatric premedication [9, 10] and procedures that
require temporary sedation (e.g. imaging) and has been
reported recently the be among the 20 most often uti-
lised medications in oncology patients associated with
toxic side effects [11]. Midazolam has been shown to
exert apoptosis-inducing properties, which are mediated
by the mitochondrial pathway in neuroblastoma cells
and primary rat neurons [12], while other modes of
cytotoxicity were reported to be predominant in other
human cell types [13]. Whereas high concentrations of
midazolam (>50 μM) induce apoptosis in a large fraction
of neuroblastoma cells and primary rat neurons, low
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concentrations of midazolam (5–10 μM) produce a slight
increase of cell viability in primary rat neurons [12]. This
effect has not been investigated in neuroblastoma cells so
far. Thus, the influence of low concentrations of midazo-
lam on cell viability in this cell line remains unknown. The
increase of cell viability might counteract the cytotoxic
effect of chemotherapeutics like TMZ and contribute to a
reduced anticancer activity of these agents. Furthermore,
no data are available, whether midazolam is able to modify
the cell cycle of neuroblastoma cells, especially in regard to
the TMZ-induced G2/M arrest.
We hypothesised, that midazolam at low concentra-
tions increases cell viability, leading to a reduced toxicity
of the anticancer agent TMZ by altering the cell cycle. A
viability assay (XTT) was performed to evaluate the
effect and toxicity of increasing concentrations of mid-
azolam and TMZ. Additionally, a bromodeoxyuridine-
based proliferation assay (BrdU) was used to estimate
the effect of midazolam to the antiproliferative effect of
temozolomide. The toxicity of TMZ (IC25, IC50 and
IC75) after pretreatment and comedication with midazo-
lam (16 μM) was investigated and cell cycle analysis was
performed to elucidate the effect of midazolam on the
primary mode-of-action of TMZ.
Methods
Materials and reagents
Roswell Park Memorial Institute 1640 medium (RPMI)
with and without phenol red and trypsin/EDTA (0.05 %/
0.02 %) were purchased from PAN-Biotech (Aidenbach,
Germany). Penicillin and streptomycin were obtained from
PAA Cell Culture Company (Cambridge, UK). NaCl, KCl,
KH2PO4 and fetal calf serum were obtained from Merck
(Darmstadt, Germany). Ethanol was obtained from Carl
Roth GmbH (Karlsruhe, Germany). Na2HPO4, DMSO,
EDTA, propidium iodide, phenazine methosulfate, TMZ
and staurosporine were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Preservative-free midazolam was
obtained from ratiopharm GmbH (Ulm, Germany). 2,3-
Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide (XTT) sodium salt was obtained from Appli-
Chem GmbH (Darmstadt, Germany).
Cell culture
Human neuroblastoma cells (SHEP) (characterised in
[14, 15]) were cultured in RPMI medium, supplemented
with 10 % heat-inactivated fetal calf serum, 2 mM L-glu-
tamine, 50 U mL−1 penicillin and 50 μg mL−1 strepto-
mycin. Cells were cultured at 37 °C in a humidified 5 %
carbon dioxide atmosphere.
Cell treatment and experimental setup
Cell viability was assessed using the XTT assay after the
following treatments: 1: increasing concentrations of
midazolam for 24 h (0, 1, 2, 4, 8, 16, 32, 64, 128, 256,
512 μM); 2: increasing concentrations of TMZ for 24 h
(control, 10, 30, 100, 300, 1000 and 2000 μM); 3:
increasing concentrations of TMZ for 24 h after pre-
treatment with midazolam 16 μM for 6 h; 4: increasing
concentrations of TMZ for 24 h after pretreatment with
midazolam 16 μM for 6 h or pretreatment + coincuba-
tion for 24 h.
Cell cycle analysis using the Nicoletti assay [16] was
performed after incubation with 1.: TMZ (0, 10, 100,
1000 μM) for 24 h, 2.: pretreatment with midazolam
16 μM for 6 h with subsequent incubation with TMZ (0,
10, 100, 1000 μM) for 24 h, 3.: TMZ (0, 10, 100,
1000 μM) for 48 h, 4.: pretreatment with midazolam
16 μM for 6 h with subsequent incubation with TMZ (0,
10, 100, 1000 μM) for 48 h.
Analysis of cell viability
The XTT assay was used for measurement of cell viability.
Briefly, XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfonyl)-2H-
tetrazolium-5-carboxanilide inner salt) is metabolised to a
coloured formazan dye in vital cells by mitochondrial
dehydrogenase. Due to the fact, that only vital cells are
capable to metabolise XTT, the amount of produced for-
mazan dye is indicative for the fraction of vital cells. To
evaluate cell viability, 100 μl of cell suspension with a cell
concentration of 105 ml−1 per well were incubated over-
night in a 96-well plate. Each well was washed with
PBS to remove unattached cells and refilled with 200 μl
colourless medium (RPMI without phenol red), supple-
mented with different concentrations of midazolam and
TMZ alone or in combination. After 24 h, 100 μl cell
culture supernatant were removed from each well and
50 μl of the dye solution were added, containing XTT
(1 mg ml−1) and phenazine methosulfate (50 μM). After
gentle mixing of the samples, the plate was incubated
for 120 min at 37 ° C. Subsequently, samples were mea-
sured spectrophotometrically at 540 nm.
Analysis of cell proliferation
A colorimetric immunoassay was used to quantify cell
proliferation. Shortly, during DNA synthesis, proliferat-
ing cells integrate the thymidine analogue 5-bromo-2’-
deoxyuridine (BrdU) instead of thymidine. Following
denaturation, a peroxidase-conjugated antibody binds
to newly incorporated BrdU. After a specific substrate
reaction with tetramethylbenzidine, spectrophotometri-
cal measurement of absorbance indicates the extent of
newly synthesised DNA as a parameter of proliferation.
In detail, 200 μl of a cell suspension containing 1x104
ml−1 cells were incubated in each well of a 96-well plate
overnight to ensure adherence and logarithmic growth.
Subsequent incubation with the investigated substances
was followed by fixing the cells and denaturation.
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Incubation with anti-BrdU-peroxidase conjugated spe-
cific antibodies to BrdU. After a washing step with
200 μl PBS and subsequent addition of 100 μl substrate
solution containing tetramethylbenzidine, absorbance
was measured at 370 nm and 492 nm (read-out absorb-
ance = absorbance370nm - absorbance492nm).
Cell cycle analysis
Cell staining with propidium iodide allows quantifying the
amount of cellular DNA, which indicates the phase of the
cell cycle. After permeabilisation and staining, the quantity
of cellular DNA is analysed by flow cytometric analysis,
using the intensity of fluorescence of the stained DNA.
Modifications of the cell cycle by drugs like TMZ are indi-
cated by a change of the flow cytometric patterns [16].
For cell cycle analysis, 2 ml of cell suspension were
incubated with a concentration of 0.5x105 cells ml−1
overnight to reach adherence. Medium was replaced and
supplemented with the investigated substance. After the
defined time period, supernatant was harvested and ad-
herent cells were detached with trypsin/EDTA 0.05 %/
0.02 % at 37 °C and added to the supernatant. After cen-
trifugation (1600 rpm, 5 min, 21 °C), the supernatant
was removed and cells were washed with 1 ml of PBS.
Subsequently, cells were incubated with 250 μl Nicoletti
buffer (containing sodium citrate dihydrate 0.1 %, Triton
X-100 0.1 % and propidium iodide 50 μg ml−1) and kept
on ice until completion of flow cytometric analysis.
Statistics
Results are expressed as means ± SD. All calculations
were made with GraphPad Prism version 5.03 for Win-
dows (GraphPad Software, San Diego, CA, USA). The
values for drug concentrations leading to 25 %, 50 % or
75 % reduction of cell viability (IC25, IC50 and IC75,
respectively) and the zero equivalent point (ZEP) were
obtained from nonlinear regression analysis for bell-
shaped dose–response relationships. Statistical analysis
was performed by means of Student’s t-Test or one-way
analysis of variance (ANOVA) with Bonferroni post hoc
test. P < 0.05 was considered significant.
Results
Cell viability after incubation with different
concentrations of midazolam
To evaluate the impact of midazolam on the viability of
neuroblastoma cells, XTT assay was performed after
incubation for 24 h with increasing concentrations of
midazolam. In particular with regard to low concentra-
tions of midazolam, small increments of concentrations
were selected.
Midazolam increased cell viability in neuroblastoma
cells at the lower concentrations used (2, 4, 8 and 16 μM),
whereas higher concentrations (128, 256 and 512 μM) led
to a profound decline of cell viability (Figure 1). Thus,
midazolam caused a hormetic response with regard to
cytotoxicity, characterised by a low-concentration stimula-
tion and a high-concentration inhibition. The "Zero
Equivalent Point" (ZEP) describes the point of reversal of
response and defines the concentration of midazolam,
which is characterised by the transition from protective to
toxic effects [17]. The ZEP of midazolam was 79.4 μM.
The IC50 of midazolam in the investigated neuroblastoma
cell line was 226.9 ± 13.2 μM.
Impact of pretreatment and pretreatment + coincubation
of midazolam to the IC25, IC50 and IC75 of temozolomide
The dose–response of TMZ was investigated without
midazolam and after pretreatment (6 h prior to TMZ
incubation) or pretreatment followed by coincubation
(6 h prior to TMZ incubation and subsequent coincuba-
tion for 24 h) with midazolam (16 μM) (Fig. 2). Pretreat-
ment with midazolam (16 μM) increased both the IC25
(1005 ± 197 μM vs. 449 ± 304 μM; P < 0.05, Fig. 3a) and
IC50 (1676 ± 557 μM vs. 925 ± 196 μM; P < 0.05, Fig. 3b).
Fig. 1 Midazolam-induced hormesis and toxicity in neuroblastoma
(SHEP) cells. Cell viability of neuroblastoma (SHEP) cells was measured
with the XTT assay to investigate cell viability after incubation for 24 h
with increasing concentrations of midazolam. The "Zero Equivalent
Point" (ZEP) describes the point of reversal of response and defines the
concentration of midazolam, which is characterised by the transition
from protective to toxic effects [17]. The ZEP of midazolam was
79.4 μM. A significant increase of cell viability in comparison to control
was detected after incubation with 2, 4, 8, and 16 μM, whereas a
significant decline was measured after incubation with 128, 256 and
512 μM midazolam (n = 8; * = P < 0.05 compared to control (0 μM
midazolam); data are expressed as mean ± SD)
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In contrast, the IC75 of TMZ was unaffected by midazo-
lam pretreatment (Fig. 3c).
Midazolam pretreatment followed by coincubation with
TMZ did not change the IC25 and IC50 of TMZ, while the
IC75 of TMZ was decreased significantly (IC75 1175 ±
221 μM vs. 2764 ± 307 μM; P < 0.05), indicating an ampli-
fication of the TMZ-induced cytotoxicity (Fig. 3a-c).
The influence of pretreatment and pretreatment +
coincubation of midazolam to the antiproliferative effect
of temozolomide
The proliferation rate of neuroblastoma (SHEP) cells
was measured using the BrdU-assay after incubation
with increasing concentrations of TMZ with and without
midazolam. Pretreatment with midazolam 6 h prior to
TMZ exposure significantly attenuated the antiprolifera-
tive effect of TMZ 1000 μM by 43.9 % (P < 0.05; Fig. 4),
whereas midazolam pretreatment for 6 h with further
coincubation for 24 h with TMZ did not alter the anti-
proliferative effect of TMZ (Fig. 4).
Affection of the cell cycle after incubation with different
concentrations of temozolomide with and without
pretreatment of midazolam
The flow cytometric measurement of propidium iodide-
stained DNA enables to discriminate different contents
of intracellular DNA in order to specify the cell cycle.
We investigated the impact of a wide range of concen-
trations of TMZ (10, 100, 1000 μM) on the fraction of
cells with a diploid DNA content indicating the G2/M
phase. No difference was detected with or without pre-
treatment of midazolam (16 μM) after incubation for
24 h. After 48 h, the fraction of cells being in the G2/M
phase was significantly increased after treatment with
TMZ (100 μM), while pretreatment with midazolam
(16 μM) did not modify this effect (Figs. 5 and 6).
Discussion
In the present study, we investigated the dose-dependent
effects of midazolam on cell viability in neuroblastoma
(SHEP) cells and the impact of midazolam pretreatment
and coapplication on the cytotoxicity and antiprolifera-
tive effects of TMZ. Furthermore, the effect on the main
anti-cancer mechanism of TMZ, the G2/M arrest, was
evaluated.
We revealed that midazolam alone induced a signifi-
cant increase of cell viability with 2, 4, 8 and 16 μM,
whereas 128, 256 and 512 μM of midazolam reduced cell
viability (IC50: 227 μM). Transition from protective to
toxic effects of midazolam was estimated to occur at
79.4 μM. When administered as a pretreatment 6 h prior
to TMZ exposure, midazolam at a stimulatory concen-
tration of 16 μM significantly increased the IC25 and
IC50 of TMZ, whereas the IC75 remained unaffected.
Pretreatment followed by coincubation abolished this ef-
fect and lowered the IC75 of TMZ as a sign of additional
toxicity. The antiproliferative effect of TMZ (1000 μM)
was significantly attenuated by pretreatment with
Fig. 2 Effect of pretreatment and coincubation with midazolam to
temozolomide induced toxicity. Cell viability of neuroblastoma (SHEP)
cells was measured using the XTT assay after incubation with
increasing concentrations of temozolomide (24 h). Black circles: relative
cell viability after incubation with TMZ (10, 30, 100, 300, 1000,
2000 μM); greys squares: pretreatment with midazolam (16 μM) for 6 h
with subsequent incubation with increasing concentrations of
temozolomide; white triangles: pretreatment with midazolam (16 μM)
followed by coincubation with temozolomide (24 h) (n = 5; data are
expressed as mean ± SD)
Fig. 3 Midazolam modifies the toxicity of temozolomide. The IC25, IC50 and IC75 (Panel a, b, and c, respectively) were calculated with nonlinear
regression analysis. Whereas pretreatment without subsequent coincubation increased the IC25 and IC50 of temozolomide, pretreatment followed
by coincubation with midazolam did not alter the IC25/IC50 of temozolomide. The IC75 was significantly decreased after pretreatment followed by
coincubation with midazolam, indicating an additive toxic effect (n = 5; data are expressed as mean ± SD; * = P < 0.05
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midazolam, whereas pretreatment followed by coincuba-
tion with midazolam had no impact. With view to cell
cycle analysis, TMZ (100 μM) increased the fraction of
cells in G2/M phase after 48 h. Pretreatment followed by
coincubation with midazolam did not affect the G2/M
arrest.
To date, data focusing on a pharmacologic interference
between the sedative midazolam and the chemotherapeu-
tic agent TMZ were lacking. Since neuroblastoma tumour
cells are a common therapeutic target of TMZ in clinical
practice, we chose an in vitro model of a human neuro-
blastoma cell line. Furthermore, the comparatively high
incidence of this tumour in childhood increases the prob-
ability of midazolam being co-applied to TMZ, therefore
possibly increasing clinical relevance of the supposed
effect on the cytotoxic potency of TMZ. However, to mir-
ror clinical practice and issues with an in vitro study has
multiple limitations in particular with view to pharmaco-
logical parameters like half-life (t1/2), peak levels, renal
and hepatic elimination and tissue concentration. Never-
theless, this study reveales first evidence, that midazolam
ameliorates the cytotoxic effects of TMZ in neuroblast-
oma cells in vitro. The time period of pretreatment with
midazolam was 6 h in our study and therefore reflects an
increased t1/2 of midazolam in children and infants com-
pared to adults [18]. As hepatic or renal impairment and
mode of administration strongly alters t1/2, a single time
period of pretreatment might not be sufficient to investi-
gate a so far unknown effect. Further evaluation is
necessary to specify the pharmacokinetic impact on the
cytoprotective effects of midazolam. One of the most
frequently discussed criticisms of pharmacologic in
vitro studies involves the concentrations of the applied
substances, as they frequently differ from plasma or tis-
sue concentrations used in clinical practice. In our
study, we used a broad spectrum of concentrations of
midazolam and temozolomide. The logarithmic increase of
the applied concentrations enabled us to discriminate small
effects of low concentrations of midazolam and the evalu-
ation of the IC25, IC50 and IC75 of temozolomide. The con-
centration of midazolam (16 μM) used for pretreatment in
our study was within the concentration range reached after
premedication and continuous sedation (0.3 - 23 μM) as
reported previously [19–21]. Nevertheless, a comparison of
in vitro and in vivo concentrations of midazolam remains
somewhat artificial. Three concentrations of TMZ were
tested with view to an expected G2/M-arrest. Solely
100 μM of TMZ induced this effect after 48 h. This con-
centration is comparable to plasma levels of patients
treated with temozolomide (72 μM), but is 10-fold higher
compared to levels of TMZ in the cerebrospinal fluid of
these patients [22]. However, effective concentrations in
targeted tissues remain unclear and further investigations
may be required to characterise the impact of TMZ at dif-
ferent tissue concentrations and time periods of treatment.
The observed increase of cell viability in a neuroblast-
oma cell line after incubation with low concentrations of
midazolam is a counterintuitive finding. Sedatives like
midazolam are known as potentially harmful agents
especially for neuronal cells with apoptosis-inducing
properties at high concentrations, as described above.
Previously, Chong and colleagues had shown that mid-
azolam is capable of protecting against reactive oxygen
species (ROS) induced cell death in B35 neuroblastoma
cells [23]. They reported that pretreatment with midazo-
lam leads to protection against ROS by induction of Akt
phosphorylation after activation of phosphoinositol-3-
kinase (PI3K). Interestingly, the pretreatment with mid-
azolam was comparable to our study design with regard
to treatment duration (8 h) and applied concentrations
of midazolam (5 and 10 μM). While their data indicate
that incubation with midazolam alone induces Akt
phosphorylation, it remains unknown, whether this
leads to increased cell viability also in the absence of
ROS and, if so, this effect could be abolished by block-
ing the phosphoinositol-3-kinase. Thus, it remains an
open question if Akt activation is involved in the viabil-
ity enhancing effect of midazolam in our present study.
Another study revealed, that midazolam (10 μM) atten-
uates the antiproliferative effect of glucose oxygen
deprivation (GOD) by modulating the profile of pro-
and antiapoptotic proteins in astrocytes [24]. As in the
study by Chong et al. [23] however, again no data were
Fig. 4 Pretreatment with midazolam reduces the antiproliferative
effect of temozolomide. Proliferation of neuroblastoma (SHEP) cells
was measured by the BrdU assay. In presence of temozolomide (TMZ)
1000 μM, pretreatment with midazolam enhanced cell proliferation,
whereas coincubation with midazolam had no significant impact to
the TMZ-induced antiproliferative effect (n = 3-4; data are expressed as
mean ± SD; * = P < 0.05)
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presented regarding the impact of midazolam alone on
cell viability. Guo and co-workers reported cytoprotective
effects of midazolam (0.4-40 μM) due to stimulation of
steroidogenesis after corticosterone-induced toxicity in rat
astrocytes [25]. Midazolam induced the release of preg-
nenolone and progesterone into the medium, while inhib-
ition of pregnenolone metabolism abolished the protective
effect of midazolam. To summarise, Akt phosporylation,
modulation of apoptosis-regulating proteins and stimula-
tion of steroidogenesis have been associated with cytopro-
tective effects of midazolam, although a positive effect like
an increase of cell proliferation and viability in the absence
of a toxic stimulus has not been reported. Therefore, the
potential role of these mechanisms for the protective prop-
erties described in our study remains unclear. Whereas
only low concentrations of midazolam were investigated in
those studies, we evaluated a broader concentration range.
This approach enabled us to observe a dose–response rela-
tionship phenomenon for midazolam, which is known as
hormesis. Hormesis is a toxicological concept, which is
defined by Kendig et al. as a “dose–response relationship
for a single endpoint that is characterised by reversal of
response between low and high doses of chemicals,
Fig. 6 Effect of pretreatment with midazolam to the G2/M arrest
induced by temozolomide. The cell cycle was analysed by flow
cytometric measurement after staining of cells with propidium iodide.
The percentage of cells with a diploid DNA content indicating the G2/
M phase of the cell cycle was detected to discriminate the expected
effect of temozolomide. Whereas no G2/M arrest was detected after
24 h, temozolomide (100 μM) induced a significant increase of G2/M
positive cells after 48 h. This effect was not attenuated by pretreatment
with midazolam (16 μM) (n = 5; data are expressed as
mean ± SD; * = P < 0.05)
Fig. 5 Analysis of the G2/M phase after incubation with temozolomide. Representative registrations of the flow cytometric analysis of neuroblastoma
(SHEP) cells after staining with propidium iodide (48 h). The percentage of cells with a diploid DNA content indicating the G2/M phase is indicated in
the upper right corner. Panel a control; Panel b temozolomide 10 μM; Panel c temozolomide 100 μM, Panel d temozolomide 100 μM with
pretreatment with midazolam (16 μM; 6 h)
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biological molecules, physical stressors, or any other initia-
tors of a response” [17]. We observed the typical inverted
u-shaped dose response curve, which indicates a hormetic
response of neuroblastoma cells after incubation with mid-
azolam and confirms a dose-dependent stimulatory and
inhibitory effect of this agent. There is considerable evi-
dence, that many endogenous mediators, drugs and toxines
can induce hormesis via receptor- and cell signaling mech-
anisms, e.g. the PI3K, ERK1/2 and p38-pathway [26]. Fur-
ther investigations are required to determine which
mechanisms are involved in the hormetic response induced
by midazolam. In contrast, TMZ did not induce a hormetic
effect in neuroblastoma cells in our study, which is in line
with previous results. Previous studies investigating con-
centrations of 0.1-10 μM TMZ revealed an anti-cancer
effect without any evidence for hormesis [27–29]. Another,
more methodological reason could be the lack of very sub-
tle graduation of low dose concentrations. However, with
view to the IC50 of both agents, the range of stimulatory
concentrations of midazolam (1.7-14 % of IC50) was com-
parable with analysed concentrations of TMZ, which did
not induce any stimulatory effect. Taken together, there is
no evidence that TMZ is involved in effects based on
hormesis [22]. Interestingly, the time course of midazolam
application has a major impact on the protective effect.
Pretreatment induced a significant increase of the IC25 and
IC50 of TMZ, whereas pretreatment with subsequent coin-
cubation amplified the toxicity at high concentrations (re-
duced IC75) of TMZ. Taken together, these findings
suggest that the attenuating properties of low-dose mid-
azolam for TMZ-induced cytotoxicity are dependent on
the timing of exposure and the magnitude of the subse-
quent toxic stimulus.
Further aspects of TMZ-induced toxicity were revealed
by the proliferation assay (BrdU), which indicated dose-
dependent inhibition of neuroblastoma cell proliferation
as expected. Pretreatment with midazolam attenuated the
antiproliferative effect of TMZ (1000 μM), whereas pre-
treatment with subsequent coincubation had no signifi-
cant impact on cell proliferation. Thus, pretreatment with
midazolam is capable to affect cell characteristics even
followed by exposure to high TMZ concentrations.
As the anticancer properties of TMZ are primarily
related to the induction of a G2 arrest of the cells, we
investigated the influence of TMZ with and without
midazolam on the cell cycle. Surprisingly, 24 h of incu-
bation with TMZ (10, 100, 1000 μM) did not lead to a
significant increase of G2/M-positive cells. The detection
of an effect on the fraction of G2/M-positive cells after
incubation with TMZ might require an appropriate
amount of cell division, which is only reached after 48 h.
This hypothesis is based on the result of cell cycle ana-
lysis after 48 h, as TMZ (100 μM) increased the fraction
of G2/M-positive cells significantly. Pretreatment with
midazolam did not alter this result, suggesting a differ-
ent mode-of-action for midazolam-induced cytoprotec-
tion. Although midazolam pretreatment does not seem
to influence the specific anticancer mechanisms of
TMZ, the increase of mitochondrial activity, as indicated
by XTT assay analysis, may contribute to the cytoprotec-
tive properties of midazolam. This fits well to the
detected hormetic effect of midazolam, as hormesis is
generally understood not to be based on a single mech-
anistic pathway, but rather reflects a complex pattern of
cellular reactions to an unspecific sublethal stimulus.
Conclusion
In this in vitro study in neuroblastoma (SHEP) cells,
midazolam induced a biphasic action with increased cell
viability after incubation at low concentrations, whereas
high concentrations led to a profound decline in cell via-
bility. Pretreatment with low concentrations of midazo-
lam attenuated the toxic effect of TMZ, whereas
pretreatment followed by coincubation had no cytopro-
tective effect. High concentrations of TMZ abolished the
cytoprotection of pretreatment with midazolam. Coincu-
bation with midazolam aggravated the toxicity of high-
dose TMZ. The antiproliferative effect of TMZ was at-
tenuated by pretreatment with midazolam. The TMZ-
induced G2/M arrest was detected after 48 h of incuba-
tion and was not attenuated by pretreatment with mid-
azolam. Our findings may indicate the possibility of
reduced anticancer effects of TMZ in patients pretreated
with midazolam and therefore justify further investiga-
tions into the interaction of chemotherapeutic agents
with frequently used comedications like midazolam and
other agents with cytotoxic potential.
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